Business Wire

REPLY

22.11.2021 09:32:03 CET | Business Wire | Press release

Share
REPLY: Reply’s Hybrid Work Research Confirms that “Hybrid work is not a passing trend”, as it Focuses on the Rapid Evolution of Technologies Designed to Support the New Ways of Working

Increased productivity and advanced collaboration are only two of the benefits the new hybrid work models bring and will soon be the new normal in the business world. This is precisely the outcome from the new Hybrid Work research carried with Reply’s Trend SONAR, the proprietary trend detection and monitoring platform based on Artificial Intelligence - with the support of PAC (Teknowlogy Group).

The research estimated the main market trends using sector studies and evidence collected from Reply customers. Data from two different clusters of countries were then compared: the “Europe-5” (Italy, Germany, France, the Netherlands, Belgium) and the “Big-5” (USA, United Kingdom, Brazil, China, India). The aim was to understand the maturity of the market after the spent year and a half of pandemic life.

Companies that have accelerated their digital transformation during the pandemic define the hybrid work model as popular, effective and performing –the very reasons why there will be no turning back.

Aside from a few limitations related to remote collaboration, which technological innovation will increasingly be able to minimise, the new normal does not provide for a full-time return to physical workplaces as before, but rather for greater flexibility and hybrid work paradigms. This approach is expected to revolutionise office design, corporate culture and the overall employee experience. This scenario will benefit employees with better work-life balance and increase of work efficiency, as well as companies: smaller office spaces, flexible working hours, hiring of talent without the need for relocation.

As Filippo Rizzante, Reply CTO, mentions: “The digital world and technology have reshaped the future of the employee experience. Regardless of the specific working context, be it an office or a factory, hybrid work will increasingly be characterised by the support and collaboration of software or hardware based on artificial intelligence. This will be facilitated by greater data literacy and a propensity for digitisation which will not only be the prerogative of developers, but will instead play a key role for the entire workforce. The transition to remote and flexible working models will, to a certain extent, become a permanent fixture and the new corporate culture will have to welcome and embrace the digital dimension as an integral part of daily work routines, facilitating social connections and communication on site, as well as remotely. What’s more, themes such as sustainability and employee well-being will increasingly become an integral part of a company’s DNA.”

To enable the hybrid work scenario, information must be accessible in the cloud and seamless and instant collaboration must be made possible through the adoption of the right tools for each business and activity. At the infrastructure level, cloud computing is not just an option, it is becoming the standard that is driving hybrid architectures. Spending on public and private cloud technologies already represents more than half of the current global infrastructure spending and this is expected to reach two thirds by 2024.

This acceleration and migration is also fuelling investments in productivity tools that consist mostly of cloud-based and intelligent technologies. Reply’s study highlights that among the Europe-5 countries, this market is expected to reach €7.6 billion by 2025. The push towards cloud computing will also drive the market of the countries that make up the Big-5 cluster, which are expected to reach a market of €36 billion.

Another trend highlighted by Reply’s research is the growth of hyperautomation; another approach based on Artificial Intelligence which extends the use of automation to value-added activities. By 2025, nearly half of the largest global companies are expected to support workers with smart technologies designed to assist with complex interactions.

Cybersecurity is also one of the main enabling technologies for hybrid work, precisely because one of the greatest obstacles to this type of work is the potential vulnerability of corporate networks. For this very reason, security is one of the major investment areas in 2021 and it is not expected to be a short-lived trend. It is estimated that by 2025 the market for end-user device security, in other words security solutions for PCs, smartphones, tablets and other corporate devices, will grow by 45% among the Big-5 countries and by 34% among the Europe-5 countries.

A strong focus on sustainability accompanies the Hybrid Work model: Reply’s research shows that the workforce, and in particular the new generations, search for companies that operate with a solid purpose, that act in a responsible and sustainable manner from an environmental point of view and that have the courage to take a stand in social and cultural debates - with clear and measurable corporate ESG standards. The well-being of the workforce, mental health and quality of life are gaining more relevance in the hybrid work environment, alongside physical safety.

Hybrid work has become an essential factor in retaining talent and when facing the great resignation phenomenon, with almost half of under 35s who, according to global data, are considering quitting their jobs if forced to return to the office full time. As the business landscape continues to change, organisations need to improve their existing capabilities and provide access to distance learning platforms. It is estimated that the Big-5’s spending on online learning platforms will increase by 48% by 2025 , reaching €16 billion, while among the Europe-5s this value will reach €2 billion.

The full research can be downloaded here . This new research is part of the Reply Market Research series, which includes the research papers on “From Cloud to Edge” , “Industrial IoT: a reality check” e “Beyond Digital Marketing ”.

Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Link:

ClickThru

Social Media:

https://www.facebook.com/ReplyinUK/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye